A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension
Latest Information Update: 21 Dec 2023
At a glance
- Drugs HGP 2102 (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 21 Dec 2023 New trial record